Overview
- Health Canada approved Dr. Reddy’s generic semaglutide on Tuesday, making Canada the first G7 country to authorize a copy of Ozempic.
- The Notice of Compliance covers 2 mg and 4 mg single‑use pens for once‑weekly treatment of adults with type 2 diabetes.
- The regulator said the product met safety, efficacy and quality standards and is pharmaceutically equivalent to the brand drug.
- Eight other generic applications remain under review, and more entrants typically push prices from about 75–85% of the brand down toward roughly 35% as competition grows, with final patient costs shaped by provincial coverage decisions.
- Dr. Reddy’s says it makes the active ingredient in‑house and will use partner OneSource in Bengaluru for commercial manufacturing as it prepares to launch in Canada.